Colorectal cancer immunotherapy-Recent progress and future directions

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Immunotherapy has revolutionized solid tumor treatment, becoming a primary approach for metastatic or recurrent cancers.
• Immune checkpoint inhibitor (ICI)-based immunotherapy shows promise in colorectal cancer (CRC) treatment, with several agents approved for advanced stages.
• Emerging immunotherapies like CAR-T cells and cancer vaccines further advance CRC treatment options.

Purpose of the Study:

• To review recent clinical trial findings on immunotherapy efficacy in colorectal cancer (CRC).
• To elucidate mechanisms of tumor-intrinsic resistance to ICIs in CRC.
• To discuss potential biomarkers for predicting immunotherapy response in CRC patients.

Main Methods:

• Literature review of recent clinical trials on immunotherapy for colorectal cancer.
• Summary of mechanisms underlying tumor-intrinsic resistance to immune checkpoint inhibitors.
• Discussion of predictive biomarkers for immunotherapy efficacy in CRC.

Main Results:

• Immunotherapy, particularly ICI-based approaches, has demonstrated significant safety and efficacy in advanced CRC.
• Various immunotherapeutic strategies, including CAR-T cells and cancer vaccines, are contributing to CRC treatment advancements.
• Understanding tumor-intrinsic resistance mechanisms and identifying predictive biomarkers are crucial for optimizing immunotherapy outcomes.

Conclusions:

• Immunotherapy represents a major advancement in the treatment landscape of colorectal cancer.
• Further research into resistance mechanisms and biomarker development is essential for maximizing the benefits of immunotherapy in CRC.
• Personalized immunotherapy strategies hold promise for improving patient survival and quality of life in CRC.